| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | -0.097 | 0.01 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.01 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.02 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.089 | 0.02 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.02 |